TuHURA Biosciences, Inc. HURA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -187.2%— | -169.2%— | —— | —— | —— | |
| Return on assets | -139.5%+73.4pp | -127%+51.2pp | -196.3%— | -136%+141pp | -212.9%+223pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 1.2×-1.8× | 0.8×-2.9× | 0.4×-1.1× | 0.8×-1.6× | 3×-2.0× | |
| Quick ratio | 1.2×-1.8× | 0.8×-2.9× | 0.4×-1.1× | 0.8×-1.6× | 3×-2.0× | |
| Cash ratio | 1×-0.3× | 0.6×-1.8× | 0.3×-1.0× | 0.6×-1.6× | 1.3×-3.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $0.39+70.1% | $0.44-44.1% | $0.33+246% | $0.44+176% | $0.23+146% | |
| Valuation | ||||||
| Market capitalization | $155.39M+45.8% | $42.74M-75.3% | $126.74M— | $102.65M— | $136.7M— | |
| Enterprise value | $149.54M+52.3% | $39.62M-75.3% | $124.12M— | $94.26M— | $130.64M— | |
| Price / book | 6.7×+1.2× | 2×-9.8× | 7.6×— | 5.3×— | 13.9×— | |
| Free cash flow yield | -17.6%-1.8pp | -64.8%-56.3pp | -19.5%— | -16.4%— | -10.1%— | |
| Earnings yield | -19.9%+6.1pp | -70.3%-57.8pp | -23.1%— | -27%— | -17.2%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do TuHURA Biosciences, Inc.'s ratios come from?
- Every ratio is computed from TuHURA Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.